An observational study to validate the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy) questionnaire

Richard R. Rubin, Mark Peyrot, Catherine P. Metzinger, Yaping Xu, Barbara Lippe, Leah McCormack, Daniel Aaron Davis

    Research output: Contribution to journalArticle

    Abstract

    Objective: The objective of this study was to psychometrically evaluate a tool to measure adult caregivers' level of satisfaction with the delivery device used to administer injections of recombinant human growth hormone (rhGH) to a child the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy*) questionnaire. Research design and methods: One hundred caregivers who administer rhGH to a child using an injection device completed the SMIGHTy questionnaire at baseline and 714 days later, and also completed other measures of treatment adherence and treatment satisfaction at baseline. Main outcome measures: SMIGHTy reliability (inter-item and testretest) and external validity (association with other study measures) were assessed. Results: Analyses revealed good inter-item agreement and testretest reliability for the SMIGHTy questionnaire. External validity, measured by associations with adherence and other measures of treatment satisfaction, was high. Study limitations: This study assessed only adult caregivers; the instrument was not validated for use by young or adult patients. Conclusions: The SMIGHTy instrument is more comprehensive than existing instruments for assessing the growth hormone treatment experience. It is multidimensional, assesses both positive and negative aspects of the treatment experience (Device Satisfaction, Negative Events, Benefits), and has separate measures of overall satisfaction and preference.

    Original languageEnglish (US)
    Pages (from-to)2009-2017
    Number of pages9
    JournalCurrent Medical Research and Opinion
    Volume27
    Issue number10
    DOIs
    StatePublished - Oct 2011

    Fingerprint

    Growth Hormone
    Observational Studies
    Injections
    Caregivers
    Therapeutics
    Human Growth Hormone
    Equipment and Supplies
    Surveys and Questionnaires
    Young Adult
    Research Design
    Outcome Assessment (Health Care)

    Keywords

    • Injectable human growth hormone
    • Patient satisfaction
    • Self-report
    • Validity

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    An observational study to validate the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy) questionnaire. / Rubin, Richard R.; Peyrot, Mark; Metzinger, Catherine P.; Xu, Yaping; Lippe, Barbara; McCormack, Leah; Davis, Daniel Aaron.

    In: Current Medical Research and Opinion, Vol. 27, No. 10, 10.2011, p. 2009-2017.

    Research output: Contribution to journalArticle

    Rubin, Richard R. ; Peyrot, Mark ; Metzinger, Catherine P. ; Xu, Yaping ; Lippe, Barbara ; McCormack, Leah ; Davis, Daniel Aaron. / An observational study to validate the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy) questionnaire. In: Current Medical Research and Opinion. 2011 ; Vol. 27, No. 10. pp. 2009-2017.
    @article{06fadeeae86e40e685205a7d6d407793,
    title = "An observational study to validate the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy) questionnaire",
    abstract = "Objective: The objective of this study was to psychometrically evaluate a tool to measure adult caregivers' level of satisfaction with the delivery device used to administer injections of recombinant human growth hormone (rhGH) to a child the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy*) questionnaire. Research design and methods: One hundred caregivers who administer rhGH to a child using an injection device completed the SMIGHTy questionnaire at baseline and 714 days later, and also completed other measures of treatment adherence and treatment satisfaction at baseline. Main outcome measures: SMIGHTy reliability (inter-item and testretest) and external validity (association with other study measures) were assessed. Results: Analyses revealed good inter-item agreement and testretest reliability for the SMIGHTy questionnaire. External validity, measured by associations with adherence and other measures of treatment satisfaction, was high. Study limitations: This study assessed only adult caregivers; the instrument was not validated for use by young or adult patients. Conclusions: The SMIGHTy instrument is more comprehensive than existing instruments for assessing the growth hormone treatment experience. It is multidimensional, assesses both positive and negative aspects of the treatment experience (Device Satisfaction, Negative Events, Benefits), and has separate measures of overall satisfaction and preference.",
    keywords = "Injectable human growth hormone, Patient satisfaction, Self-report, Validity",
    author = "Rubin, {Richard R.} and Mark Peyrot and Metzinger, {Catherine P.} and Yaping Xu and Barbara Lippe and Leah McCormack and Davis, {Daniel Aaron}",
    year = "2011",
    month = "10",
    doi = "10.1185/03007995.2011.613922",
    language = "English (US)",
    volume = "27",
    pages = "2009--2017",
    journal = "Current Medical Research and Opinion",
    issn = "0300-7995",
    publisher = "Informa Healthcare",
    number = "10",

    }

    TY - JOUR

    T1 - An observational study to validate the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy) questionnaire

    AU - Rubin, Richard R.

    AU - Peyrot, Mark

    AU - Metzinger, Catherine P.

    AU - Xu, Yaping

    AU - Lippe, Barbara

    AU - McCormack, Leah

    AU - Davis, Daniel Aaron

    PY - 2011/10

    Y1 - 2011/10

    N2 - Objective: The objective of this study was to psychometrically evaluate a tool to measure adult caregivers' level of satisfaction with the delivery device used to administer injections of recombinant human growth hormone (rhGH) to a child the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy*) questionnaire. Research design and methods: One hundred caregivers who administer rhGH to a child using an injection device completed the SMIGHTy questionnaire at baseline and 714 days later, and also completed other measures of treatment adherence and treatment satisfaction at baseline. Main outcome measures: SMIGHTy reliability (inter-item and testretest) and external validity (association with other study measures) were assessed. Results: Analyses revealed good inter-item agreement and testretest reliability for the SMIGHTy questionnaire. External validity, measured by associations with adherence and other measures of treatment satisfaction, was high. Study limitations: This study assessed only adult caregivers; the instrument was not validated for use by young or adult patients. Conclusions: The SMIGHTy instrument is more comprehensive than existing instruments for assessing the growth hormone treatment experience. It is multidimensional, assesses both positive and negative aspects of the treatment experience (Device Satisfaction, Negative Events, Benefits), and has separate measures of overall satisfaction and preference.

    AB - Objective: The objective of this study was to psychometrically evaluate a tool to measure adult caregivers' level of satisfaction with the delivery device used to administer injections of recombinant human growth hormone (rhGH) to a child the Satisfaction Measure of the Injection of Growth Hormone Therapy (SMIGHTy*) questionnaire. Research design and methods: One hundred caregivers who administer rhGH to a child using an injection device completed the SMIGHTy questionnaire at baseline and 714 days later, and also completed other measures of treatment adherence and treatment satisfaction at baseline. Main outcome measures: SMIGHTy reliability (inter-item and testretest) and external validity (association with other study measures) were assessed. Results: Analyses revealed good inter-item agreement and testretest reliability for the SMIGHTy questionnaire. External validity, measured by associations with adherence and other measures of treatment satisfaction, was high. Study limitations: This study assessed only adult caregivers; the instrument was not validated for use by young or adult patients. Conclusions: The SMIGHTy instrument is more comprehensive than existing instruments for assessing the growth hormone treatment experience. It is multidimensional, assesses both positive and negative aspects of the treatment experience (Device Satisfaction, Negative Events, Benefits), and has separate measures of overall satisfaction and preference.

    KW - Injectable human growth hormone

    KW - Patient satisfaction

    KW - Self-report

    KW - Validity

    UR - http://www.scopus.com/inward/record.url?scp=80053013754&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=80053013754&partnerID=8YFLogxK

    U2 - 10.1185/03007995.2011.613922

    DO - 10.1185/03007995.2011.613922

    M3 - Article

    C2 - 21919819

    AN - SCOPUS:80053013754

    VL - 27

    SP - 2009

    EP - 2017

    JO - Current Medical Research and Opinion

    JF - Current Medical Research and Opinion

    SN - 0300-7995

    IS - 10

    ER -